<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">antibiotics</journal-id><journal-title-group><journal-title xml:lang="ru">Антибиотики и Химиотерапия</journal-title><trans-title-group xml:lang="en"><trans-title>Antibiot Khimioter = Antibiotics and Chemotherapy</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">0235-2990</issn><publisher><publisher-name>ООО «Издательство ОКИ»</publisher-name></publisher></journal-meta><article-meta><article-id custom-type="elpub" pub-id-type="custom">antibiotics-180</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL PAPERS</subject></subj-group></article-categories><title-group><article-title>Изучение активности противовирусных препаратов в отношении возбудителя лихорадки Зика в культуре клеток</article-title><trans-title-group xml:lang="en"><trans-title>The Study of Antiviral Drugs' Activity Against The Causative Agent of Zika Fever in Cell Culture</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Логинова</surname><given-names>С. Я.</given-names></name><name name-style="western" xml:lang="en"><surname>Loginova</surname><given-names>S. Ya.</given-names></name></name-alternatives><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Щукина</surname><given-names>В. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Shchukina</surname><given-names>V. N.</given-names></name></name-alternatives><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Борисевич</surname><given-names>Г. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Borisevich</surname><given-names>G. V.</given-names></name></name-alternatives><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Суровяткина</surname><given-names>И. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Surovyatkina</surname><given-names>I. V.</given-names></name></name-alternatives><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Борисевич</surname><given-names>С. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Borisevich</surname><given-names>S. V.</given-names></name></name-alternatives><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>48 Центральный НИИ Министерства обороны Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>48th Central Scientific Research Institute of the Ministry of Defence of the Russian Federation</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2018</year></pub-date><pub-date pub-type="epub"><day>08</day><month>05</month><year>2020</year></pub-date><volume>63</volume><issue>9-10</issue><fpage>14</fpage><lpage>18</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Логинова С.Я., Щукина В.Н., Борисевич Г.В., Суровяткина И.В., Борисевич С.В., 2020</copyright-statement><copyright-year>2020</copyright-year><copyright-holder xml:lang="ru">Логинова С.Я., Щукина В.Н., Борисевич Г.В., Суровяткина И.В., Борисевич С.В.</copyright-holder><copyright-holder xml:lang="en">Loginova S.Y., Shchukina V.N., Borisevich G.V., Surovyatkina I.V., Borisevich S.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.antibiotics-chemotherapy.ru/jour/article/view/180">https://www.antibiotics-chemotherapy.ru/jour/article/view/180</self-uri><abstract><p>Вирус Зика (ZIKV) является представителем вирусов рода Flavivirus, семейства Flaviriridae, и относится к зоонозным арбовирусным инфекциям, переносимым комарами рода Aedes. В организме человека этот флавивирус вызывает заболевание, известное как лихорадка Зика, этиологически родственное жёлтой лихорадке, лихорадкам денге, Западного Нила и Чшсунгунья. Специфического лечения лихорадки Зика нет, вакцина или же химиопрепараты на сегодняшний день также отсутствуют. Проведенный сравнительный анализ эффективности химиопрепаратов, индукторов интерферона и двух классов интерферона α-, β-, и γ- показал, что препараты интерферона эффективно подавляют репродукцию вируса Зика в культуре клеток Vero в широком диапазоне концентраций. Химиопрепараты Триазавирин®, Виразол®, Зовиракс®, Цитарабин® и Интавирин® не влияли на репродушппо вируса Зика, штамм MR 766V, в культуре клеток Vero. В присутствии Виразола® и Рибавирина® в концентрации 100 мкг/мл статистически значимо снижался размер негативных колоний вируса Зика.</p></abstract><trans-abstract xml:lang="en"><p>Zika virus (ZIKV) is a representative of the viruses of the genus Flavivirus in the family Flaviviridae, it belongs to the zoonotic arbovirus infections transmitted by mosquitoes of the genus Aedes. In humans, this flavivirus causes a disease known as zika fever, etymologically related to yellow fever, dengue, West Nile and Chikungunya viruses. There is no specific treatment for zika fever, just as there is no vaccine or preventive measures available to date. A comparative analysis of the effectiveness of chemotherapy medications, interferon inducers and two classes of interferon α-, β-, and γ- showed that interferon drugs effectively inhibit the reproduction of Zika virus in Vero cell culture in a wide range of concentrations. Chemotherapy medications Triazavirin®, Virazole®, Zovirax®, Cytarabine®, and Ingavirin® did not affect the reproduction of Zika virus strain MR 766V in Vero cell culture. The size of negative Zika virus colonies was significantly reduced in the presence of Virazole® and Ribavirin® at a concentration of 100 μg/ml. zika virus, Triazavirin®, Ribavirin®, Ingavirin®, Reaferon-EU®, Rebif(fila)®, antiviral efficacy</p></trans-abstract><kwd-group xml:lang="ru"><kwd>вирус Зика</kwd><kwd>Триазавирин®</kwd><kwd>Рибавирин®</kwd><kwd>Ишавирин®</kwd><kwd>Реаферон-ЕС®</kwd><kwd>противовирусная эффективность</kwd><kwd>культура клеток</kwd></kwd-group><kwd-group xml:lang="en"><kwd>Rebif(/31a)®</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Mumtaz N., van Kampen J.J., Reusken СБ., Boucher C.A., Koopmans M.P. Zika Virus: Where Is the Treatment? Curr Treat Options Infect Dis 2016; 8: 208-211. doi: 10.1128/CMR.00072-15.</mixed-citation><mixed-citation xml:lang="en">Mumtaz N., van Kampen J.J., Reusken СБ., Boucher C.A., Koopmans M.P. Zika Virus: Where Is the Treatment? Curr Treat Options Infect Dis 2016; 8: 208-211. doi: 10.1128/CMR.00072-15.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Frumence E. Roche M., Krejbich-Trotot P. The South Pacific epidemic strain of Zika virus replicates efficiently in human epithelial A549 cells leading to IFN-? production and apoptosis induction. Virology 2016; 493: 217-226. doi: 10.1016/j.virol.2016.03.006.</mixed-citation><mixed-citation xml:lang="en">Frumence E. Roche M., Krejbich-Trotot P. The South Pacific epidemic strain of Zika virus replicates efficiently in human epithelial A549 cells leading to IFN-? production and apoptosis induction. Virology 2016; 493: 217-226. doi: 10.1016/j.virol.2016.03.006.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Shao W., Espenshade P.J. Expanding roles for SREBP in metabolism. Cell. Metab 2012; 16: 414-419. doi: 10.1016/j.cmet.2012.09.002.</mixed-citation><mixed-citation xml:lang="en">Shao W., Espenshade P.J. Expanding roles for SREBP in metabolism. Cell. Metab 2012; 16: 414-419. doi: 10.1016/j.cmet.2012.09.002.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Soto-Acosta R. Bautista-Carbajal P., Syed G. H., SiddiquiA., Del Angel R. M. Nordihydroguaiaretic acid (NDGA) inhibits replication and viral morphogenesis of dengue virus. Antiviral Res. 2014; 109: 132—140. doi: 10.1016/j.antiviral.2014.07.002.</mixed-citation><mixed-citation xml:lang="en">Soto-Acosta R. Bautista-Carbajal P., Syed G. H., SiddiquiA., Del Angel R. M. Nordihydroguaiaretic acid (NDGA) inhibits replication and viral morphogenesis of dengue virus. Antiviral Res. 2014; 109: 132—140. doi: 10.1016/j.antiviral.2014.07.002.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Syed G. K, SiddiquiA. Effects of hypolipidemic agent nordihydroguaiaretic acid on lipid droplets and hepatitis С virus. Hepatology. 2011; 54: 1936-1946. doi: 10.1002/hep.24619.</mixed-citation><mixed-citation xml:lang="en">Syed G. K, SiddiquiA. Effects of hypolipidemic agent nordihydroguaiaretic acid on lipid droplets and hepatitis С virus. Hepatology. 2011; 54: 1936-1946. doi: 10.1002/hep.24619.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">NourA. M. Li Y., Wolenski J., Modis Y. Viral membrane fusion and nucleocapsid delivery into the cytoplasm are distinct events in some flaviviruses. PLoS Pathog 2013; 9: el003585. doi.org/10.1371/joumal.ppat.1003585.</mixed-citation><mixed-citation xml:lang="en">NourA. M. Li Y., Wolenski J., Modis Y. Viral membrane fusion and nucleocapsid delivery into the cytoplasm are distinct events in some flaviviruses. PLoS Pathog 2013; 9: el003585. doi.org/10.1371/joumal.ppat.1003585.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Potlara J. J, Laster S. М., Petty I. Т. Inhibition of poxvirus growth by Terameprocol, a methylated derivative of nordihydroguaiaretic acid. Antiviral Res 2010; 88: 287-295. doi: 10.1016/j.antiviral.2010.09.017.</mixed-citation><mixed-citation xml:lang="en">Potlara J. J, Laster S. М., Petty I. Т. Inhibition of poxvirus growth by Terameprocol, a methylated derivative of nordihydroguaiaretic acid. Antiviral Res 2010; 88: 287-295. doi: 10.1016/j.antiviral.2010.09.017.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Chen Q. Nordihydroguaiaretic acid analogues: their chemical synthesis and biological activities. Curr Top Med Chem 2009; 9: 1636—1659.</mixed-citation><mixed-citation xml:lang="en">Chen Q. Nordihydroguaiaretic acid analogues: their chemical synthesis and biological activities. Curr Top Med Chem 2009; 9: 1636—1659.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Grossman S. A. Ye X., Peereboom D., Rosen/eld M. R., Mikkelsen Т., Supko J. G, Desideri S. Phase I study of terameprocol in patients with recurrent high-grade glioma. Neuro Oncol 2012; 14: 511—517. doi: 10.1093/neuonc/nor230.</mixed-citation><mixed-citation xml:lang="en">Grossman S. A. Ye X., Peereboom D., Rosen/eld M. R., Mikkelsen Т., Supko J. G, Desideri S. Phase I study of terameprocol in patients with recurrent high-grade glioma. Neuro Oncol 2012; 14: 511—517. doi: 10.1093/neuonc/nor230.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Руководство по экспериментальному (доклиническому) изучению новых фармакологических веществ. М.: Минздрав РФ, 2013; 942с. / Rukovodstvo ро provedeniju doklinicheskih issledovanij lekarstvennyh sredstv. chast' 2. M.: Minzdrav R.F., 2005. [In Russian]</mixed-citation><mixed-citation xml:lang="en">Руководство по экспериментальному (доклиническому) изучению новых фармакологических веществ. М.: Минздрав РФ, 2013; 942с. / Rukovodstvo ро provedeniju doklinicheskih issledovanij lekarstvennyh sredstv. chast' 2. M.: Minzdrav R.F., 2005. [In Russian]</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Eyer L., Nencka ., Huvarovd I., Palus M., Joao Alves M., Gould E.A., De Clercq E., Riizek D. Nucleoside Inhibitors of Zika Virus. J Infect Dis. 2016; Sep 1; 214 (5): 707-711. doi: 10.1093/infdis/jiw226. Epub 2016 May 27.</mixed-citation><mixed-citation xml:lang="en">Eyer L., Nencka ., Huvarovd I., Palus M., Joao Alves M., Gould E.A., De Clercq E., Riizek D. Nucleoside Inhibitors of Zika Virus. J Infect Dis. 2016; Sep 1; 214 (5): 707-711. doi: 10.1093/infdis/jiw226. Epub 2016 May 27.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Boding C, Kuhn R.J. Novel approaches to flavivirus drug discovery. Expert. Opin Drug Discov2012; 7 (5): 417-428. doi: 10.1517/1760441. 2012.673579. Epub 2012 Mar 22.</mixed-citation><mixed-citation xml:lang="en">Boding C, Kuhn R.J. Novel approaches to flavivirus drug discovery. Expert. Opin Drug Discov2012; 7 (5): 417-428. doi: 10.1517/1760441. 2012.673579. Epub 2012 Mar 22.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
